Saturday 17 October 2026
Export IMMX’s income statement to Excel — free account
Immix Biopharma, Inc.
IMMX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 18.2% and free cash flow fell 116.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.98
0.70
−8.06%
Follow IMMX
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 2.85 | 0.68 | 1.40 | 1.26 | 1.34 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 6.31 | 8.68 | 7.75 | 6.88 | 7.73 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 2 | 2 | 11 | 17 | 21 | 21 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | (1) | (1) | (24) | (8) | (16) | (22) | (29) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (1) | (1) | (24) | (8) | (16) | (22) | (29) | |||||
| Depreciation | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (0.29) | (0.34) | (6.64) | (0.59) | (0.89) | (0.76) | (0.89) | |||||
| Cash flow | — | — | — | (0.23) | (0.12) | (0.43) | (0.53) | (0.66) | (0.52) | (0.73) | |||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.04) | (0.02) | |||||
| Free cash flow | — | — | — | (0.24) | (0.12) | (0.43) | (0.53) | (0.66) | (0.56) | (0.75) | |||||
| Book value | — | — | — | (1.08) | (1.40) | 4.90 | 0.95 | 0.93 | 0.47 | 2.85 | |||||
| Shares, m | — | — | — | 3 | 3 | 4 | 14 | 17 | 28 | 33 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (1) | 0 | (2) | (7) | (11) | (15) | (24) | ||||
| Capex | — | — | — | 0 | — | 0 | — | 0 | (1) | (1) | |||||
| Free cash flow | — | — | — | (1) | 0 | (2) | (7) | (11) | (16) | (25) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | (4) | (5) | 18 | 14 | 16 | 12 | 91 | ||||
| Total debt | — | — | — | — | 4 | — | — | — | — | — | |||||
| Net debt | — | — | — | (1) | 4 | (18) | (13) | (18) | (18) | (100) | |||||
| Shareholders’ equity | — | — | — | (4) | (5) | 18 | 13 | 16 | 13 | 94 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (206.34) | (154.86) | (260.35) | (49.73) | (88.57) | (100.82) | (46.07) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | (244.50) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | 0.00 | 27.41 | (367.80) | (52.84) | (105.07) | (146.76) | (55.00) | |||||
Negative figures in brackets.
Charts ten years each
Immix Biopharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SANA Sana Biotechnology, Inc. | $740.9M | — (loss-making) | — | — | n/m | −5.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IVA Inventiva S.A. Sponsored ADR | $740.0M | — (loss-making) | — (loss-making) | −10.77% (below 0%: shrinking) | n/m | −20,989.22% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LXRX Lexicon Pharmaceuticals, Inc. | $734.2M | — (loss-making) | — (loss-making) | −97.60% (below 0%: shrinking) | n/m | −154.09% (below 0%: shrinking) | 94.36% | (3,835.26%) | Compare |
| IMMX Immix Biopharma, Inc. | $719.6M | — (loss-making) | — | — | n/m | −116.22% (below 0%: shrinking) | — | 0.00% | |
| ACHV Achieve Life Sciences, Inc. | $717.2M | — (loss-making) | — | +54.44% (above 0%: growing) | n/m | −19.01% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FDMT 4D Molecular Therapeutics, Inc. | $711.0M | — (loss-making) | — (loss-making) | +25,106.67% (above 0%: growing) | n/m | −61.28% (below 0%: shrinking) | 100.00% | (2,037.16%) | Compare |
| ANL Adlai Nortye Ltd. Sponsored ADR | $710.1M | — | — | — | — | +46.03% (above 0%: growing) | — | — | Compare |
| OABI OmniAb, Inc. | $687.7M | — (loss-making) | — (loss-making) | +244.24% (above 0%: growing) | n/m | +211.16% (above 0%: growing) | 95.45% | (49.47%) | Compare |
| ANNX Annexon, Inc. | $682.5M | — (loss-making) | — | — | n/m | −26.41% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $714.1M | — | — | +54.44% | — | −22.71% | 0.00% | 0.00% |
Immix Biopharma, Inc. (IMMX) key facts
- Immix Biopharma, Inc. (IMMX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, IMMX traded at $7.98, a market capitalization of $719.6 million.
- Return on equity was −55.0% and debt-to-equity 0.00.